ScinoPharm’s pre-filled syringe and liquid injectable products, and lyophilized injectables passed the FDA’s pre-approval on-site inspections in March and October 2022.
ScinoPharm Taiwan, Ltd. (1789) and Nano Targeting & Therapy (NTT) initiated an agreement for a licensing mode technology transfer in December 2022 to establish a collaborative development plan based on a technology that utilizes mesoporous silica nanoparticle (MSN) to deliver docetaxel to treat brain cancer.
ScinoPharm Taiwan (stock code 1789) announced its consolidated revenue for 2020 of NTD 3.083 billion, after-tax net profit of NTD 282 million, and after-tax earnings per share of NTD 0.36. Faced with the highly uncertain global market last year and COVID-19, the company has maintained stable operations according to its original strategy.
ScinoPharm Taiwan (1789), an all-round niche pharmaceutical company, has been actively investing in business transformation and strengthening the internal integration of resources in recent years, and the results have gradually emerged.
ScinoPharm Taiwan (stock code 1789), a company specializing in the development of highly complex active pharmaceutical ingredients (APIs) and injectable formulations, announced that for the first half of 2019, its consolidated revenue totaled NTD 1.39 billion, net profit after tax was NTD 0.136 billion, and after-tax earnings per share were NTD 0.17. The consolidated revenue dropped by 24.76% on a year-on-year basis.
